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REVIEW
Modeling and Simulation Approaches for Cardiovascular
Function and Their Role in Safety Assessment
TA Collins1, L Bergenholm2, T Abdulla2, JWT Yates3, N Evans2, MJ Chappell2* and JT Mettetal4*
Systems pharmacology modeling and pharmacokinetic-pharmacodynamic (PK/PD) analysis of drug-induced effects on
cardiovascular (CV) function plays a crucial role in understanding the safety risk of new drugs. The aim of this review is to
outline the current modeling and simulation (M&S) approaches to describe and translate drug-induced CV effects, with an
emphasis on how this impacts drug safety assessment. Current limitations are highlighted and recommendations are made
for future effort in this vital area of drug research.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 175–188; doi:10.1002/psp4.18; published online on 11 March 2015.
Cardiovascular (CV) function is essential for life; the heart
efficiently pumps blood containing vital nutrients and oxy-
gen through vessels to cells throughout the body and
removes waste products and carbon dioxide. CV function is
controlled by the central nervous system, autonomic nerv-
ous system, and endocrine system, and is able to respond
to a variety of external stimuli, while feedback mechanisms
maintain homeostatic control. It adapts to the body’s needs;
for example, during exercise the heart rate (HR) increases,
causing an increase in cardiac output (CO), and the propor-
tion of CO is increased to muscles. Drug-induced CV side
effects are undesirable because they may cause long-term
CV damage, which puts the patient at greater risk of mor-
tality and morbidity.
CV function declines with age: stiffened arteries lead to
increased systolic arterial pressure,1 and a reduction in
maximum HR causes a compensatory stroke volume (SV)
increase in order to maintain CO during, e.g., exercise.2
Therefore, as the general population ages, more patients
are likely to present with preexisting CV conditions, which
when combined with drug-induced CV changes could result
in even greater risks. Understanding and predicting the
consequences of these safety changes are challenges for
the development of new drugs.
Mathematical modeling of drug effects and the CV sys-
tem can aid this understanding, and there are numerous
examples of pharmacokinetic-pharmacodynamic (PK/PD),
mechanistic, and systems pharmacology approaches in the
literature. In this review, modeling analyses are explored in
these three approaches defined as:
1. Traditional ‘‘top-down’’ PK/PD modeling and simulation (M&S) that
utilizes empirical or descriptive models to describe the linkage
between drug concentration and observed response, such as
change in functional or structural CV biomarkers.
2. Mechanistic or systems biology ‘‘bottom-up’’ approaches that com-
bine knowledge of the system from cellular targets to their impact
at a cellular, tissue, or whole-body level.
3. Systems pharmacology3 ‘‘middle-out’’ approaches that sit at the
interface between the other two categories. These combine aspects
of both PK/PD and systems biology, and incorporates physiological
processes and mechanism of action at targets.
M&S approaches promise greater impact in the CV safety
space by integrating in silico, in vitro, and in vivo preclinical
data with mechanism-based models to anticipate and predict
the effects of new drugs in humans.4 The application of these
principles is now beginning to become reality in CV safety
research, although it is important not to overlook earlier
empirical PK/PD models that have been used in cross-
species comparison of CV PK/PD relationships. Prospective
predictions of human effects at expected therapeutic doses
is a vital component of preclinical CV safety risk assessment
for potential new drugs and is a rapidly developing area of
interest. However, this is only valuable if clinical data can be
obtained and compared to the model-based predictions. If
differences between predicted and observed magnitude and
kinetics of drug-induced effects can be better understood,
then progress in refinement of prospective predictions of CV
safety endpoints can be achieved.
OVERVIEW OF DRUG-INDUCED CARDIOVASCULAR
EFFECTS
A wide panel of electrophysiological and mechanical func-
tional markers is collected during clinical and preclinical in
vivo testing. These are outlined in Figure 1 and typically
include:
1. Electrocardiograph (ECG) measurements. Common ECG interval
measurements include QT interval, QRS duration, and PR intervals,
all measured in milliseconds (ms). The QT interval is often cor-
rected for HR, defined as corrected QT (QTc).
2. Hemodynamic measurements including HR and blood pressure
(BP), measured in beats min-1 and mmHg, respectively.
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3. Indices of contractility including the maximum and minimum rate of
left ventricular pressure change (dP/dt max (1) and dP/dt min (–)),
measured in mmHg s-1, and QA interval, which is an inverse index
measured in ms (time between Q wave on ECG and onset of arte-
rial wave (blood pressure)). Ejection fraction (EF) is a common clin-
ical biomarker measured as the percentage of the diastolic volume
of blood in the ventricle that is ejected with each beat.
4. In preclinical pathological studies, chronic changes such as histopa-
thology of the heart and/or vessels are also monitored.
Functional changes of ECG and hemodynamics,
although not typically life-threatening in themselves, are
readily monitorable, although they may be associated with
more serious but rare events. Most famously, QT/QTc pro-
longation is known to be a risk factor for the potentially fatal
arrhythmia Torsades de Pointes (TdP), which caused one-
third of drug withdrawals between 1990 and 2006.5 In addi-
tion, prolongation of the PR and QRS intervals are linked to
CV mortality and morbidity in cardiac risk populations.6 HR
and BP changes are known to increase risk to all causes of
mortality, including CV complications.7,8 Contractility
changes typically require measurements through more
technical or invasive techniques and are therefore more dif-
ficult to obtain clinically, but can lead to heart failure, hyper-
trophic cardiomyopathy, and sudden cardiac death.9 Other
examples of cardiac safety liability include the withdrawal of
rofecoxib, a selective Cox-2 inhibitor, from the market after
long-term use showed increased risk of serious thrombotic
events including myocardial infarction and stroke.10
Cardiovascular complications were the leading cause of
drug withdrawals from the EU market during 2002 and
201111 across a range of therapy areas. Any unintended
drug-induced effects on the CV system represent a poten-
tial safety concern, and in order to avoid costly late-stage
failures, a variety of early preclinical experiments were per-
formed in vitro, in silico, and in vivo to rule out unsafe com-
pounds or to understand and quantify risk with those that
do progress. Novel therapeutics must distinguish them-
selves from standard of care agents either in terms of
improved efficacy or safety risk, so a thorough assessment
of CV effects is essential.
Preclinical Safety studies with CV endpoints include:
1. ‘‘Off-target’’ activity assessed in vitro on molecular targets
(enzymes, GPCRs, ion channels) associated with effects on CV
structure and function.
2. In silico and quantitative structure–activity relationships (QSAR)
models built using data from such in vitro ‘‘off-target’’ data.
3. In vitro functional assessments using traditional tissue-based studies
(e.g., isolated heart/blood vessel pharmacology), supplemented with
new technologies such as human stem cell-based cardiomyocytes.
4. In vivo functional assessment is mainly run in conscious animals
and measures ECG, BP, and HR via implantable telemetry in
single-dose, safety pharmacology studies at the therapeutic range
and above.12
5. In vivo assessment of the effects on CV structure in repeat-dose
toxicology studies assessing clinical pathology, histopathology, and
clinical observations. Functional assessments of HR and ECG can
also be made in such studies using jacketed telemetry.
All of these endpoints contribute to an integrated CV risk
assessment of the drug before it is first administered to
humans. In the following sections we cover modeling
approaches applied to drug-induced effects on ECG
Figure 1 Standard minimally invasive and invasive CV measurements that can be obtained from a whole body system. The Wiggers
diagram (top right) shows the dynamics of some measurable variables, including atrial and ventricular pressure as well as ventricular
volume. Also, a standard 12-lead ECG curve is shown, and the main intervals (QT, QRS, and PR) indicated.
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intervals, hemodynamics (including contractility), and car-
diac damage, and where appropriate, highlight examples of
translation from preclinical to humans.
DRUG-INDUCED CHANGES ON ECG INTERVALS
The ECG reflects the electrical depolarization and repolari-
zation that cardiomyocytes undergo during an action poten-
tial (AP). It represents a combined view of the spread of
excitation that occurs across the cardiac tissue. Changes in
ECG intervals can indicate changes in cardiac electrophysi-
ology, for example, resulting from ion channel inhibition.
One of the most frequently assessed ECG intervals is
QT, and with increasing concern regarding QT/QTc prolon-
gation, the ICH announced in 2005 preclinical (S7B)13 and
clinical (E14)14 regulatory guidance for new drugs. These
focused on QT prolongation and blockade of the ion chan-
nel (Kv11.1) encoded by the human ether-a-go-go-related
gene (hERG). The E14 guidelines states that in thorough
QT/QTc (TQT) studies, the threshold level of regulatory
concern is at 5 ms, as evidenced by an upper bound of the
95% confidence interval (CI) around the mean effect on
QTc exceeding 10 ms.15 PK/PD modeling of QTc prolonga-
tion has been beneficial in this setting for predicting QTc
prolongation at doses that were not directly studied in the
TQT study and to support statistical analysis.
Biomarkers such as QT prolongation are sensitive, but
not specific, predictors of ventricular proarrhythmia (i.e.,
TdP), which can be complicated by further mechanisms, for
example, multiple ion channel blockade or effects on traf-
ficking of the ion channel to the cell membrane. PK/PD
modeling of QT prolongation began in the late 1970s (see
Table 1 and Supplementary Material for references).
Arguably, this is the most characterized of all PK/PD rela-
tionships of ECG interval changes due to the regulatory
focus on the link between hERG, QT, and TdP. In earlier
reviews of drug-induced QT effects,16,17 the following fac-
tors have been identified as important to consider during
the modeling of QT, but could also remain relevant for other
ECG endpoints:
1. Heart rate correction, preferably individual-specific.
2. Variability of baseline, both interindividual and intraindividual, as in
circadian rhythm.
3. Subject demographic information such as age, sex.
4. Genetics, e.g., rare polymorphisms causing long QT syndrome.
5. Environmental or other factors such as obesity, physical activity,
electrolyte levels, blood pressure, blood glucose, and alcoholism.
QT interval duration is strongly dependent on HR and the
use of correction methods aim to remove the influence of
heart rate, providing a more stable measure: QTc. HR cor-
rection formulas include linear and fixed exponential
(Bazett, QTcB, Fridericia, QTcF, and individual, QTcI). QTcI
and QTcF have been shown to perform best in humans,
while QTcI performed best in preclinical species including
dog, guinea pig, and cynomolgus monkey.18 Cosine func-
tions19 have been used to account for within-subject vari-
ability in baseline due to homeostatic mechanisms, external
factors, or circadian rhythm (regular diurnal fluctuation),
either using typically single or where necessary multiple
cosine functions.20,21 In one example of QTc prolongation
modeling, the model structure utilized three baseline cosine
functions with time periods of 4, 8, and 24 hours in the
dog, and 2, 4, and 24 hours in human, combined with
effect compartment models for both species and for the
concentration–response relationship an Emax model for the
dog and a linear model for human.22
PK/PD modeling efforts have focused on QT and hERG
inhibition, but there are other examples of other mechanisms
affecting ECG intervals, Table 1 describes the type of struc-
tural models used in the descriptive PK/PD modeling of
drug-induced ECG interval changes for both preclinical and
clinical studies. Currently, PK/PD modeling of clinical or non-
clinical data is routinely modeled using population (mixed
effects) approaches rather than individual or pooled data-
sets.22,23 Interindividual variability is often included on base-
line parameters and drug effect. This reflects the availability
of high-quality, rich ECG data combined with more readily
available software to conduct these analyses.
Linear, Emax, and sigmoidal Emax models have all been
used to describe the relationship between concentration
and effect for ECG intervals.19 58% of the compounds
listed could be adequately described with simple linear
drug effect models. While it is expected that drug effects
will eventually saturate with exposure, linear models may
be more prevalent for ECG changes, as maximal effects
are often not achieved in safety studies where doses are
selected based on margins to therapeutic exposure not to
characterize the full concentration–response relationship.
Studies can also be halted before reaching a maximum
level due to lack of tolerability at these exposures. However,
Emax or sigmoidal Emax models are often used with antiar-
rhythmic compounds when these exposures are tolerated.
Once in the clinic, concentrations required to reach maxi-
mal effect are less often reached for these same reasons,
leading to even fewer saturable models being observed.24
Where Emax models have been utilized for clinical QTc
changes, the maximal activity level appears to be
compound-specific rather than reaching a system-specific
or physiological upper limit (for example, 20 ms for verna-
kalant25 and 170 ms for N-acetylprocainamide26).
It is very common to observe a delay between blood or
plasma drug concentration and CV effect, resulting in hys-
teresis observable on a concentration–effect plot. This time
delay is often short, on the order of minutes. Under these
circumstances a link, or effect compartment, model is often
applied,19 describing the delay between the measured
plasma concentrations and the distribution of drug to the
effect site using a single rate constant, ke0. Thus, 43% of
compounds included a time delay, 89% of these used an
effect compartment model. For ECG intervals the observed
time delay rarely exceeds a half-life of 30 minutes, although
two compounds, AZD3839 and AZD1305, had time delays
that exceeded 100 minutes in the dog.20,22 Notably these
compounds were also modeled in human and delayed
effect was not as apparent, only 10–15 minutes. The use of
indirect response models19 that describe the physiological
turnover of the response parameter in terms of synthesis
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and degradation is uncommon for ECG intervals. One
potential reason for this is that the effect of the drug on ion
channel activity is expected to be rapid once the compound
has reached the myocytes, not requiring a turnover process
to have an effect. In addition to delays in reaching the site
of action, another potential cause of observed time delays
could be the production of an active metabolite.27
Although PK/PD modeling examples of intervals other
than QT are limited, it appears most other endpoints are
typically treated similar to QT, although heart rate correc-
tion may not always be required for other ECG intervals.
While not as well studied, CV complications are still poten-
tially hazardous with these endpoints. Cav1.2 inhibition
leads to increased PR interval and is linked to AV block,
while Nav1.5 inhibition leads to increased QRS duration
and is linked to ventricular tachycardia. The concentration–
QRS relationship of a number of compounds has been
investigated in dog23 using a population approach, and this
enabled comparison across compounds and investigation
of the therapeutic window. The data were modeled as per-
cent change from baseline and the size of the estimated
Emax for QRS change varied from 8 to 57%.
In contrast to the descriptive PK/PD modeling
approaches, drug-induced ECG effects have also been
Table 1 Overview of the composition of PK/PD models used for modeling of ECG intervals in preclinical species and human, indicating selected
concentration–effect relationship, model for capturing potential time delays and baseline function
Variable Species Concentration–effect relationship Baseline function Time delay model
QTc Human Linear: disopyramide,1,2 quinidine,3–5
sotalol,6–8 N-acetylprocainamide,9
sematilide,10 dofetilide,11 citalopram,12
lamotrigine,13a prulifloxacin,14a
moxifloxacin,8,13,14 grepafloxacin,8
mifepristone,15a cabazitaxel,16a
AZD1386,17 NCE01-0318
Exponential: AZD383919
Emax: disopyramide,
20
N-acetylprocainamide,9 sematilide,10
azimilide,21 AZD130517
Emax sigmoidal: dofetilide,
11
vernacalant22
Operational agonism: dofetilide23
Constant: sotalol,3,7 sematilide,10
dofetilide,11 citalopram,12
mifepristone,15 cabazitaxel,16
azimilide,21 AZD1305,17 vernacalant22
1x cosine: sotalol,8 moxifloxacin,8
grepafloxacin,8 NCE01-0318
3x cosine: AZD383919
Unknown cosine: lamotrigine,13
moxifloxacin,13 AZD138617
Effect compartment: disopyramide,1
quinidine,3,4 sotalol,7
N-acetylprocainamide,9
sematilide,10 dofetilide,11
citalopram,12 AZD1305,17
AZD383919
QTc Rat Linear: quinidine,24 roxithromycin,25
azithromycin25
Emax: terfenadine,
24 clarithromycin,25
erythromycin,26 ebastine27
Effect compartment: roxithromycin,25
azithromycin,25 clarithromycin,25
erythromycin,26 ebastine27
QTc Guinea pig Linear: Imipramine,28 fluvoxamine28
Emax: tacrolimus
29
Effect compartment: Imipramine,28
fluvoxamine28
Myocardial compartment: tacrolimus29
QTc Dog Linear: AZD1305,17 AZD1386,17
cisapride,30 sotalol,30 moxifloxacin,30
Compound 2,31 quinidine,32
NCE01-0318
Emax: AZD3839
19
Emax sigmoidal: dofetilide,
33
cisapride,34,35 moxifloxacin,34
terfenadine,35 E-403135
Constant: cisapride,34,35
moxifloxacin34
Linear: dofetilide33
Unknown cosine: AZD1305,17
AZD138617
1x cosine: cisapride,30 sotalol,30
moxifloxacin,30 NCE01-0318
3x cosine: AZD383919
Effect compartment: AZD1305,17
quinidine,32 dofetilide,33 cisapride,35
terfenadine,35 E-4031,35
AZD383919
QTc Monkey Linear: Compounds 1,8,9,31
Moxifloxacin36
Model Cmax-Emax: Compounds
8–931
QRS Human Linear: quinidine,3,5 cabazitaxel,16a
flecainide37,38
Constant: cabazitaxel,16 flecainide37,38 Effect compartment: quinidine3
QRS Dog Linear: R155139
Emax sigmoidal: Compounds 3–7
31
HR-dependent: flecainide40
Constant: R155139
HR-dependent: flecainide40
Effect compartment: R155139
QRS Monkey Linear: R1551 Constant: R155139
PQ Human Linear: quinidine3 Effect compartment: quinidine3
PR Human Linear: cabazitaxel16a Constant: cabazitaxel16
PR Dog Linear: R1551 Constant: R155139 Effect compartment: R155139
PR Monkey Linear: R1551 Constant: R155139 Effect compartment: R155139
ERP Rabbit Exponential: AZ13395438,41
Compound A and 2f42
Constant: AZ13395438,41
Compound A and 2f42
Effect compartment: AZ13395438,41
Compound A and 2f42
aStudies where no ECG effect was found. References contained in Supplementary Material.
ERP, effective refractory period.
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modeled using detailed, “bottom-up” mechanistic models.
Drug effects on ion channels are described mathematically
to predict morphology changes in the AP or ECG. Cellular
cardiac AP models have been developed for different spe-
cies including human,28–31 dog,32 guinea pig,33 and rabbit.34
These models represent the relevant electrophysiological
aspects of the cellular system: transmembrane conduct-
ance, ion channels and their inhibition by drugs, as well as
other pumps/exchangers and intracellular ion concentra-
tions, and integrate the influence of these factors over time
on cellular ion concentrations. Drug effects are modeled by
altering the ion conductance term, which represents the gat-
ing (open/closed, etc.) of the relevant ion channel.
Such cardiac AP models have been applied to predict
the effects of antiarrhythmic drugs that alter ion channel
activities35–37 and better describe the effects of multiple ion
channel inhibition than focusing purely on potency values.
Davies et al.35 calibrated the Hund-Rudy canine AP
model32 to predict change in AP duration in dog cardiomyo-
cytes solely from in vitro data of five ion channels (Nav1.5,
Cav1.2, Kv4.3, Kv7.1, and Kv11.1), demonstrating a predic-
tivity of 68% (ratio of sum of true positive and true negative
results to total number examined). Similarly, Mirams et al.37
showed that a human AP model could be trained to classify
TdP risk based on predicted therapeutic Cmax and Nav1.5,
Cav1.2, and Kv4.3 channel median inhibitory concentration
(IC50) values with markedly improved accuracy compared
to safety margins between hERG IC50 and therapeutic
Cmax alone. A recent comparison of predicted effect of ion
channel block in AP models from human and preclinical
species highlights the importance of cautious extrapolation
between species.38 For example, a 70% block of the hERG
ion channel resulted in an 80% AP prolongation in humans
but only a 30% and 20% change in dog and guinea pig,
respectively.
While these ion flux models can capture information
relating to the membrane potential in a single cell, the
resulting ECG are at the tissue/whole-body level (Figure 2)
and depend in part on the spatial orientation of myocytes in
the heart and the AP propagation in tissue. Models of car-
diac tissue have therefore been constructed to describe the
propagation of the AP in 1, 2, and 3 dimensions39 by linking
multiple cellular models in a spatially relevant way. These
tissue models have been used to study the effects of single
and multiple ion channel blockade on Purkinje fibers.40
Sotalol-induced effects41 have been studied via pseudo-
ECG generated from the simulation of a one-dimensional
fiber representing proportional distribution of cells of the
epicardium, midmyocardium, and endocardium. At the
whole-heart level, cardiac structure and electrophysiology
have been integrated with whole-body geometry to translate
ion channel effects through simulation of cardiac AP
Figure 2 Spatial and temporal scales at which cardiovascular systems models operate. At each level, different assumptions and varia-
bilities need to be addressed, to meet the ultimate goal of predicting cardiovascular liabilities in patient populations.
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propagation to calculate 12-lead ECG and QT prolongation
as measured in the torso.42 A 12-lead ECG was also calcu-
lated by Wilhelms et al.43 for comparison of the two QTc-
prolonging drugs cisapride (proarrhythmic) and amiodarone
(antiarrhythmic), identifying the effect of amiodarone alone
on AP conduction as the mechanism behind the drug being
anti- rather than proarrhythmic.
The usefulness of mechanistic in silico models in drug
discovery and development now needs to be demonstrated,
as a recent study44 that investigated the ability of AP mod-
els to predict the QT change in TQT studies and showed
the models in general underpredicted the TQT outcome.
These became more reliable predictions of TQT outcome
when the comparison range was relaxed to within a 100-
fold range of concentration reached in the TQT study,
suggesting simple concentration comparisons between
modeled AP changes and in vivo plasma exposure–
response requires improvement by considering other factors
such as tissue distribution and intracellular concentrations.
One tool built specifically to do this is the Cardiac Safety
Simulator (CSS) (Certara), a commercially available tool
designed to increase the ability of nonmodelers to test the
effect of ion channel activity on the ECG incorporating pop-
ulation variability on both exposure (through SimCYP, Cer-
tara) and ECG prediction. As a test of predictivity of the
simulator, the QTc effects of six antipsychotic drugs45 were
investigated using the CSS, showing good agreement
between predicted and observed mean QTc change,
although the predictions did not account for all of the
observed variability. This approach represents a bottom-up
approach based purely on in vitro data and it is potentially
tempting to adopt this as a predictive strategy but not
enough is yet known about the predictive performance of
this tool. With a vast number of inputs and settings in such
a model, this should be used cautiously until more validated
examples are demonstrated, and it is hoped this will
explore more diverse situations such as mixed ion channel
inhibition, combined effect of parent and metabolite, and
mechanisms not caused by ion channel inhibition.
In our experience AP changes can be routinely predicted
once in vitro ion channel inhibition assay data are gener-
ated, forming a key part of the early risk assessment prior
to in vivo data being generated. During the drug discovery
process ion channel inhibition liability can often be reduced
or removed via structural modification of potential drug enti-
ties, meaning only small changes will be observed in vivo
or only at high safety margins. PK/PD modeling of in vivo
ECG changes is then applied wherever statistically signifi-
cant changes are observed. This PK/PD modeling then
defines the underlying concentration–response relationship
and better quantifies safety margins. If a compound is then
selected to enter clinical studies, a prediction will be made
at expected therapeutic doses in human combining the pre-
dicted human PK and the PD model including any time
delays to assess the expected magnitude of effect.
While mechanistic modeling provides a powerful lens,
empirical PK/PD modeling will still remain a valuable
approach to quantifying the concentration–effect relation-
ship of ECG intervals from both the clinical and preclinical
studies in the near future, because it is an effective way to
assess CV safety risk and the models are straightforward
to implement with little mechanistic understanding. Mecha-
nistically based models of ECG change have focused pri-
marily on ion channel inhibition as the typical mechanism of
effect, but due to early in vitro safety screens it is likely that
in the future observed in vivo effects on ECG intervals will
be small, and may be driven by other, more unusual mech-
anisms. While much effort has been invested in the devel-
opment of mechanistic models that replicate the time
course of ECG changes, it is unclear how and at what point
these will be used in the drug development process. In vitro
data becomes available early in drug evaluation, when
there is limited understanding of likely exposure in human.
Later, once the human dose and pharmacokinetic predic-
tions are better defined and one could use the mechanistic
model of ECG change, the in vivo CV results become avail-
able and could take precedence over the in vitro-based pre-
diction in the integrated risk assessment.
DRUG-INDUCED CHANGES ON HEMODYNAMICS
Hemodynamics is the study of blood circulation, which is
governed by pressures and resistances in different parts of
the cardiovascular system, as well as the force and rate of
contraction of the heart. Typically, HR and BP are moni-
tored including mean arterial, diastolic, and systolic blood
pressure (MAP, DBP, and SBP, respectively). Other impor-
tant variables include stroke volume (SV), cardiac output
(CO), total peripheral resistance (TPR), contractility, and in
some cases compliance and central venous pressure. The
anatomy and physiology of the CV system result in funda-
mental interrelationships existing between these variables,
including that CO is the product of HR and SV, MAP is the
product of CO and TPR and others; for example, HR and
contractility are known to be highly correlated in vivo.46
Despite this understanding, PK/PD modeling of drug effects
is often conducted separately on individual parameters.23
Table 2 describes the application of PK/PD models to
blood pressure, heart rate, and contractility effects. Base-
line functions are widely used to explain the inherent vari-
ability and circadian rhythm, such as cosine functions. 76%
of compounds adopt indirect response models to describe
the time delay between concentration and effect, rather
than a simple effect compartment model more commonly
used for ECG intervals. In contrast to the observed time
delays with ECG intervals, the time delays on hemody-
namic parameters are far more varied, and half-lives of the
indirect response parameter kout could be within a few
minutes to greater than 50 days. This is likely to reflect the
variety and timescales of mechanisms by which a com-
pound can affect hemodynamics. The use of indirect
response models may better capture biological processes
downstream of receptor activity, but upstream of CV func-
tion, for example, nitric oxide production. The underlying
exposure response models most typically include linear or
Emax/sigmoidal Emax pharmacodynamic models.
HR changes were observed with an anti-HIV agent with
j-opioid agonist activity.47 In the dog and human studies,
effects were modeled using a single cosine function for
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baseline daily variation and a direct linear drug effect. The
mean drug effect slope was 2.3-fold steeper in dog com-
pared to that observed in human and therefore the predic-
tion of human response was made by using the dog slope
and combining it with human PK, which slightly overesti-
mated the clinical HR change. As a predictive strategy this
is a sensible approach and represents a worst-case sce-
nario, although in order to assess applicability across a
range of mechanisms additional drugs would need to be
assessed in a similar manner in order to ascertain if there
are any consistencies in cross-species differences in drug
effect for HR.
Since many hemodynamic measurements result from
interacting mechanical and physiological processes, exam-
ples of mathematical descriptions of hemodynamics have
been constructed with a systems approach in mind. These
include the regulation of CO by the peripheral tissues of
the body48 and the 2-element Windkessel model,49 which
describes the heart and circulation as a closed system cir-
cuit, including a pump and chamber containing a pocket of
air.
A computational physiological model was published in
1972 by Guyton et al.50 describing long-term blood pres-
sure and cardiac output control and was later expanded.51
These modeling works were instrumental in illustrating the
role of the renal system in long-term fluid balance and BP
control. More recent efforts to develop systems pharmacol-
ogy models (Figure 3) have generally focused on shorter-
term drug effects, and therefore attempt to combine the
relationships between HR, BP (also incorporated as mean
arterial pressure, or MAP), CO, TPR, and SV, and can be
further expanded to include contractility and compliance.
Homeostatic feedback from MAP is most commonly imple-
mented on HR, CO, SV, and via sympathetic activity to
vasculature and is analogous to the mechanism of barore-
ceptor feedback, which regulates arterial pressure.
One such example has been applied to the clinical
effects of nicardipine and nifedipine,52 which are L-type cal-
cium channel blockers. The model introduces an additional
feature by capturing this feedback through dual mecha-
nisms of the proportional and rate-sensitive functions of
MAP. Since only HR and MAP are typically observed, while
the model includes additional state variables for CO, TPR,
and SV, the system suffers structural identifiability issues. A
more recent structural identifiability analysis53 resulted in a
parameter reduction of the model, resolving this issue.
Systems pharmacology models have been applied in
rat54,55 that try to resolve the identifiability issues by the
Table 2 Overview of the composition of PK/PD models used for modeling of hemodynamic parameters in preclinical species and human, indicating selected
concentration–effect relationship, model for capturing of potential time delays and baseline function
Variable Species Concentration–effect relationship Baseline function Time delay
BP (including models of
MAP, SBP, and DBP)
Human Linear: eprosartan,43 prazasin,44
trimazosin,44 doxazosin,44,45 E708046
Emax: moxonidine,
47 fimasartan,48
Emax sigmoidal: Remifentanil
49
Constant: Remifentanil,49 prazasin,44
trimazosin,44 doxazosin,44,45
E7080,46 nifedipine50
2x cosine function: eprosartan,43
fimasartan,48 moxonidine47
Effect compartment: Remifentanil,49
eprosartan,43 prazasin,44
trimazosin,44 doxazosin44,45
IDR: E7080,46: fimasartan48
BP (including models of
MAP, SBP, and DBP)
Rat Linear: milrinone51
Log-linear: metabolites52
Emax/Imax: L-NAME,
51 doxazosin51
Sigmoidal Emax: IIDN,
52
IMDN,52 ISDN52
Constant: IIDN,52 IMDN,52 ISDN52
S€allstr€om baseline53: L-NAME,51
milrinone,51 doxazosin51
IDR: L-NAME,51 milrinone51
BP (including models of
MAP, SBP, and DBP)
Guinea pig Emax/Imax: milrinone,
51
Doxazosin,51 L-NAME51
Linear: L-NAME,51 milrinone,51
doxazosin51
IDR: milrinone51
BP (including models of
MAP, SBP, and DBP)
Dog Linear: milrinone,51
Compound 12,31 doxazosin51
Emax/Imax: L-NAME
51
Constant: Compound 1231
Cosine function: L-NAME,51
milrinone,51 doxazosin51
IDR: L-NAME,51 milrinone,51
Compound 1231
HR Human Linear: PF-0082138554
Emax/Imax: PF-00610355,
55
cilobradine56
Negative Gaussian function:
PF-0061035555
Indirect periodic function with
exercise: cilobradine56
Cosine function: PF-0082138554
Effect compartment:
PF-0061035555
Transduction: cilobradine56
HR Rat Linear: milrinone51
Emax/Imax: L-NAME,
51 doxazosin51
Operational model of agonism: CPA57
Constant: CPA57
S€allstr€om baseline53: L-NAME,51
milrinone,51 doxazosin51
IDR: L-NAME,51 doxazosin,51
milrinone51
HR Guinea pig Emax/Imax: milrinone,
51
doxazosin51 L-NAME51
Linear: L-NAME,51
milrinone,51 doxazosin51
IDR: milrinone,51
doxazosin51
HR Dog Linear: milrinone,51
PF-0082138554 doxazosin51
Threshold linear: Compound 10,31
Emax/Imax: L-NAME
51
Cosine function: L-NAME,51
milrinone,51 doxazosin,51
PF-0082138554
IDR: L-NAME,51 milrinone51
dP/dt max Dog Linear: Compound 1131 Constant: Compound 1131 IDR: Compound 1131
References contained in Supplementary Material. IDR, indirect response model.
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monitoring of CO during the model building process. In this
approach data from six compounds were combined in order
to estimate the rat model parameters. The advantage of
these types of models is the ability to determine the site of
drug effect, and these have so far been applied to TPR,
HR, SV, and CO, although notably direct drug effects on
contractility and BP have not been studied in a mechanistic
manner.
These hemodynamic models only account for total CO
and MAP; however, the blood pressure profile (Figure 1)
contains much more information about the heart contraction
as driven by the action potential. Calcium plays a critical
role in modulating contraction56: its cellular influx following
depolarization is an indirect activator of myofilaments (Fig-
ure 2). This process is sensitive to myofilament stretching
as the heart fills with blood, resulting in a stronger contrac-
tion, and is an important autoregulatory mechanism. Cellu-
lar models have therefore been used in describing this
interplay between the kinetics of calcium gradient and the
dynamics of myocyte contraction57–59 as well as their con-
trol via the autonomic nervous system. Adrenergic and
muscarinic receptors mediate this process, and drugs can
be antagonists at these receptors which may cause
changes in indexes of contractility or other effects, such as
beta-blockers (beta1 adrenoreceptor antagonists), which
are used in the treatment of hypertension. To further link
AP with hemodynamics, models have been produced
describing the electromechanics of the whole heart,60,61
and these have combined cell excitation/contraction (EC)
coupled with heart mechanics, system circulation,62 and
autonomic control.63,64 While great progress has been
made defining multiscale systems approaches (Figure 2),
these have not yet been fully utilized for linking drug expo-
sure with cardiovascular changes for the assessment of
safety or efficacy.
In our experience, modeling hemodynamic changes for
safety assessment often consists of two stages depending
on the questions to be addressed. First application of a
top-down PK/PD approach to the observable of greatest
concern allows us to quantify the effects and reveals the
steady-state concentration–response relationship. With this
information in hand, one can either assess the margin
between projected efficacious and safe exposures or use
predicted human pharmacokinetics to generate a predicted
magnitude of response at therapeutic doses. PK/PD model-
ing of hemodynamic parameters has been demonstrated
Figure 3 Comparison of existing hemodynamic systems pharmacology model structures including inter-relationships between variables
and feedback structure. References contained in Supplementary Material.66–70
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successfully and is useful for studies when only a single
hemodynamic parameter changes over time and when little
or none is known about the underlying mechanism.
Second, existing systems pharmacology models can be
applied to HR and BP data to provide insight into the mech-
anism of drug effect and the effects on the system as a
whole. If system parameters already exist,54 we can fix
these and only vary the drug-specific properties. When
modeling species without preexisting systems parameters,
we may need to develop a unique set of system parame-
ters prior to using the system or modify the system param-
eters from other species. There is not yet feedback from
the clinic to understand how successful these systems
approaches are in clinical predictions.
In the future it is expected that systems pharmacology
models will incorporate the simple interrelationships
between BP and HR, and may overcome the identifiability
issues experienced in some existing models. There will
also be future opportunities to explore bottom-up
approaches that have not been applied to drug-induced
changes in hemodynamics.
LINK BETWEEN ACUTE FUNCTIONAL EFFECTS AND
CARDIAC DAMAGE
Long-term damage or risk of CV failure is often associated
with perturbations of the cardiovascular parameters
reviewed above. Structural damage can arise as a conse-
quences of direct drug toxicity (such as necrosis of heart
tissue including the valves of the heart), but can also be an
indirect consequence of drug-induced dysfunction of hemo-
dynamic or ion channel effects over time. These effects,
however, are often poorly characterized. For example, even
the link between concentration, QTc prolongation, and TdP,
the incidence of drug-induced TdP in all patients taking the
drug is likely to be very low and is not well quantified, with
less than 4% of all TdP reporting fatalities.5 Other forms of
cardiovascular damage may also have similarly low inciden-
ces of life-threatening or fatal events, and are equally diffi-
cult to link back to exposure of the drug.
Cardiotoxic agents, which are characterized by dysfunc-
tion of cardiac or vascular smooth muscle, can cause65:
1. Myocardial infarction
2. Venous thromboembolism
3. Cardiac arrest
4. Necrosis (e.g., cocaine)
5. Valve damage66
Most analyses of the risk of cardiovascular damage and
other events concentrate on environment or diet-induced
effects and markers of disease progression (Table 3). How-
ever, there are a number of examples of statistical analyses
associating drug use with cardiovascular changes. Almost
all of these studies considered treatment by a particular
drug, or the actual dose level, and in no case were PK- or
concentration-dependent effects explored. These studies
also tended to be long-term and/or retrospective across
multiple drugs, and so PK analysis was most likely unfeasi-
ble. These were frequently retrospective studies and so
exact dose levels were also probably missing, explaining
the lack of detailed exposure-driven analysis. Systems
approaches to cardiovascular biomarkers for heart failure
Table 3 Mathematical approaches to predict cardiac damage
Drug class Analysis method Endpoint Conclusions
Cox2 inhibitors58 Multivariate odds ratios
on use or not of drug
MI and cardiac death Rofecoxib use increases the risk of serious coronary
heart disease compared with celecoxib use.
Naproxen use does not protect against serious
coronary heart disease
Hormone replacement
therapy59
Logistic regression Venous thromboembolism Current use of hormone replacement therapy was
associated with a higher risk of venous
thromboembolism, although the risk seemed to be
restricted to the first year of use.
Bendectin and others60 Pairwise comparison on
mothers use of drug
during pregnancy
Congenital Heart Disease In particular, aspirin use in early pregnancy was
associated with about a twofold increase in the
frequency of defects in septation of the
truncus arteriosus
Cox2 inhibitors61 Proportional hazards on
use and high/low dose
MI Rofecoxib significant effect. Aspirin reduces the effect
Appetite suppressants62 Pairwise comparison vs.
control and frequency
of event vs. drug use
Cardiac valve regurgitation Significant effects for some of the drugs considered
Dopamine agonists63 Pairwise comparison of risk Cardiac valve regurgitation Significant effects for some drugs
Third generation oral
contraceptives64
Pairwise comparisons Venous thromboembolism Risk of venous thromboembolism was slightly
increased in users of third generation oral
contraceptives compared with users of second
generation products.
ADHD drugs in children65 Cox hazard ratios Serious cardiovascular events
(sudden cardiac death,
acute myocardial infarction,
and stroke)
No significant effect though upper CI points to
doubling of events
References contained in Supplementary Material. MI, myocardial infarction.
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are now being recognized,67 although there are no exam-
ples known to date that link such biomarkers to PK/PD
modeling. This is potentially an important application of sys-
tems modeling to enable the discovery of cardiovascular
damage signature based on blood-borne biomarkers: Many
markers of cardiovascular disease suffer, on their own,
from a lack of specificity versus sensitivity.
TRANSLATIONAL APPROACHES
Several types of modeling approaches have been brought
to bear on cardiovascular safety, employing various levels
of mechanistic insight. One of the major values of modeling
for safety assessment is as translational tools to make pro-
spective predictions about drug effects in humans. Figure 4
describes some of the model-based translational approaches
that have been investigated to date, namely, phenomenologi-
cal PK/PD methods, bottom-up systems models, and semi-
mechanistic systems pharmacology approaches. Each of
these has specific utilities and benefits in the translational
context.
Cross-species comparative assessment using
descriptive PK/PD modeling and simulation,
or “top-down” approaches
The traditional PK/PD framework allows quantification of
the biological exposure–response relationship for better
determining safe exposures. By integrating data across
doses and timepoints, it can capture delayed effects, noisy
data, or baseline variation over time that would be more dif-
ficult to analyze through the application of standard statisti-
cal approaches. PK/PD models have been fitted to data
with multiple compounds from preclinical species (dog) and
human and then the concentration–response relationship
compared.20 They proceeded to use the relationship to pre-
dict the likely QTc change of a compound over a specific
concentration range that was about to enter clinical studies;
however, the concentrations required to reach 10 ms were
never reached in human to fully support the prediction
made. In similar cross-species comparisons21,68 the proba-
bility of reaching 10 ms was estimated for dog and human
and this could also be used for prospective predictions. We
noticed the reported mean slopes were 7–20-fold higher
in human than dog, and had concerns that the dog model
was less sensitive than that used in Parkinson et al.20;
therefore, we adopted the Parkinson et al. comparative
assessment as our predictive strategy for compounds
showing QTc prolongation in dog studies.
By carrying out these PK/PD modeling analyses it can
help to identify a pharmacokinetic driver of the safety
response, for example, Cmax, AUC, or moving average of
drug exposure, providing a means to potentially optimize
the therapeutic index through appropriate study design.69
This is particularly important when effects have a slow
onset (days or weeks) in comparison to daily concentration
fluctuations, and the data collected over a prolonged time-
scale may necessitate a simplification of exposure to drive
the PD model.
While a PK/PD modeling and simulation approach is val-
uable in making predictions about an alternative study
design under similar conditions, one limitation is that they
do not inherently take into account underlying physiological
differences across species such as expression levels,
impact of different baseline values to level of absolute
change, and different turnover rates. It is likely that homeo-
static mechanisms, especially for hemodynamic parame-
ters, could obscure the underlying concentration–response
relationship to different extents across species.
Incorporation of drugs with varied or even multiple mech-
anisms20 in these cross-species analyses can mitigate sit-
uations when a signal is observed preclinically and a
Figure 4 Schematic and graphical description of commonly adopted translational approaches for drug-induced CV changes and their
relative use of systems information. 1. Comparative assessment between species using descriptive PK/PD modeling and simulation to
identify predictive in vitro/in vivo assays and quantify empirical translational relationship. 2. Bottom-up systems pharmacology approach
using in vitro potency to predict clinical effects based on mechanistic knowledge. 3. In vivo systems pharmacology approach to predict
clinical effects based on systems knowledge and in vivo data.
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human prediction is required, but the mechanism is
unknown or not well understood.
Bottom-up systems pharmacology model using in vitro
potency
The bottom-up approach utilizes mechanistic knowledge of
the system, allowing the input of in vitro data for prediction
of in vivo effects, similar to in vitro to in vivo extrapolation
(IVIVE) in PK prediction. However, purely in vitro systems
approaches must prove their value as translational tools
and part of the challenge is to understand how these scale
from cellular dynamics to the whole-body system
(Figure 2). While understanding how the single endpoint of
in vitro inhibition compared to in vivo change is a standard
part of the integrated preclinical risk assessment,70 now in
silico predictions allow assessment of the combined effects
on multiple molecular targets. This is done by combining
models at a cellular level (for example, with AP models),44
with a multiscale approach that scales the cellular results
up to the in vivo situation (pseudo-ECG). In the example
with antipsychotics61 the predicted QTc effects reasonably
replicated the mean observed effects. Another example
predicts (through a combination of different models and
techniques) the PK and PD (QTc prolongation) of domperi-
done (metabolized by CYP3A) and ketoconazole (CYP3A
inhibitor) in a patient population.71 The effect of co-dosing
on PK and PD was investigated, and despite having some
issues predicting baseline, and some inconsistencies in the
predicted and observed effects, it reproduced the study
conclusions fairly well.
To date, this approach has been used to demonstrate
translation largely for ion channel inhibition and QTc
effects,45,71 although there is systems biology knowledge
and therefore the potential for a similar approach to be
applied incorporating contractility and hemodynamics. A
purely in vitro-driven approach to predicting clinical CV
changes has not yet been attempted by us but we look for-
ward to the time when this would sit alongside the more
established PK/PD approach.
Systems pharmacology, or “middle-out” approaches
The final type of approach represents a middle-out3
approach that attempts to combine the best properties of
the purely descriptive top-down and reductionist bottom-up
approaches. For example, comprehensive in vivo systems
pharmacology models are in existence for CV system
behavior, particularly for hemodynamics,52,54,55 but these
have so far only been implemented in a single species,
making translational predictions from preclinical species to
human difficult. We do not have feedback from the clinic
yet to understand how successful human predictions have
been and there are no reports of cross-species comparisons
with these models. Alternatively, simplified model structures
can be applied that capture the relevant process governing
information flow without over-parameterization.23,47 Models
of cardiovascular function with similar structure, but with
species-specific parameters could allow for further refine-
ment of the predictive power of these approaches. In these
approaches, substituting human physiological parameters
into the preclinical model is a key part of the translation. For
example, when HR changes have been translated from dog
to human using a PK/PD approach,47 the sensitivity to drug
in addition to a baseline typical for human were applied. In
another example where BP was translated using an indirect
response model, a human baseline and rate of turnover
(kout) for SBP and DBP was obtained from the literature and
combined with a PK prediction and the drug sensitivity
obtained in dog to successfully predict effects in first-time-in-
human studies.23
In contrast to the purely phenomenological approaches,
a key component of both the bottom-up and middle-out
approaches is the distinction between drug-specific and
physiological relevant system-specific parameters. While
drug-specific pharmacodynamic parameters describe the
interaction of the drug in terms of target affinity and target
activation, system-specific parameters describe the proc-
esses of the biological system.72 Physiologically based PK
models are an example that have been used in this sense
and have successfully been used to make human PK pre-
dictions and estimate doses.73
There is great opportunity to expand on existing knowl-
edge to bring translational understanding to the forefront of
preclinical safety pharmacology assessment through a sys-
tems pharmacology approach, but there should be a bal-
ance between complexity and simplicity (what can actually
be ascertained from the measurements or data available in
practice). While a systems approach is preferable for trans-
lational purposes, it requires understanding or derivation of
the drug effect mechanism. It must be acknowledged that
when the drug effect mechanism is understood and well
characterized, complex translational models can be
adopted to give a robust translational prediction with certain
underlying assumptions. However, when a mechanism is
less understood or is a combination of effect mechanisms,
it will be more challenging to make translational predictions
and simpler approaches should be adopted that rely on
fewer assumptions.
DISCUSSION
With the continued pressures on increasing productivity of
the R&D pipeline, M&S approaches are becoming standard
practice across preclinical and clinical development, and
are frequently used to analyze and translate experimental
data for decision making. There exists a tremendous oppor-
tunity to leverage these approaches in the context of trans-
lational safety, particularly for cardiovascular endpoints
where a deep understanding of anatomy and physiology
exists across species, along with quantitative high-
resolution time-course data from in silico, in vitro, preclini-
cal, and clinical cardiovascular assays. Most of the effort in
modeling drug-induced cardiovascular changes has fallen
into three categories: PK/PD models of cardiovascular end-
points, systems pharmacology models such as hemody-
namics, and in vitro-driven systems biology models. PK/PD
models have allowed direct comparison across species for
QTc prolongation and in vitro-driven systems biology mod-
els for ECG changes are coming to fruition, since the
observed effects are well linked to a mechanism (ion
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channel inhibition) and therefore great progress has been
made in this area towards reaching well-understood transla-
tion to human.
While physiologically based systems approaches for
hemodynamics have been in use since the 1970s, there
are very few applications of such models for understanding
drug effects on the system. So far investigations of human
translation have been limited, which may reflect the com-
plexity of mathematical models required as well as the rela-
tively recent need to reduce attrition in the clinic due to
such safety issues. There are several factors that on a
practical level may contribute to the limited progress in the
area of hemodynamics: first, the lack of appropriate moni-
torable biomarkers in this complex system that potentially
give rise to difficulties in parameter estimation or structural
identifiability issues. Second, the investigation of effects on
functional hemodynamic parameters is typically over a rela-
tively short (24-hour) timescale, which may not allow drug-
induced effects or feedback/disease processes over longer
timescales to be observed or quantified in a systems
model. Finally, the link to mechanism is often less clear for
hemodynamic and contractility effects: the number and
nature of molecular targets that could be involved is varied
and therefore may be difficult to combine in an in vitro-
driven systems model.
As mechanistic models become further advanced and
gain traction in the coming years, we also expect that
empirical modeling approaches will remain relevant in the
safety space. This is partly because many of the known
mechanisms of action for adverse events can be built into
in vitro screens, and therefore in discovery compounds can
be selected that do not interact with these targets. When
effects are then observed in vivo, they may frequently be
due to as yet unidentified mechanisms, making the use of
bottom-up models more difficult.
While standard dog telemetry is the model of choice to
investigate preclinical CV risk and make a quantitative trans-
lation to human, it is largely set up to investigate acute, func-
tional, tightly PK-driven effects such as ECG effects. This
type of study was originally designed for statistical analyses
looking for significant differences between vehicle and com-
pound dosed groups, and the standard designs have not
changed considerably in recent years. It is typically a cross-
over design in which each dog receives a vehicle dose and
three different doses of the drug under investigation with
monitoring for up to 24 hours postdose. In order to maximize
the utility of dog data there is a need for a strong, collabora-
tive, working relationship between those conducting the
study and those performing modeling on the ensuing data,
to ensure that the study design is appropriate for the effect
and the expected model structure if known. Further chal-
lenges to model building include incorporating the impact of
feeding effects and blood sampling on the CV endpoints that
can introduce unexplained or random error in a model if not
appropriately accounted for.55 The relative sparsity of blood
sampling for pharmacokinetic assessment during telemetry
experiments can prove difficult when trying to build a robust
pharmacokinetic model.
In addition to increased interpretability and translatability,
modeling approaches can provide a strong 3R’s (reduction,
refinement, replacement of animal usage) benefit, as they
allow for greater insight to be drawn from smaller numbers of
animals and can use prediction to avoid unnecessary studies.
Much discussion has taken place concerning the replacement
of in vivomodels entirely with in silico approaches.74
The most informed translation of drug-induced human
changes will require knowledge of underlying physiology to
be combined with systems pharmacology approaches so
drug potency can be obtained from experimental data. In
these scenarios, drug potency can be identified in a preclin-
ical setting and would then be combined with human sys-
tem parameters and other relevant information to make a
well-validated prediction of effects in humans, and this has
been shown in other areas such as myelosuppression.75
This approach has enormous potential to aid decision-
making and risk assessment on the progression of new
drugs into the clinic through their predictive capacity. Fur-
ther, application of these systems models promise to
increase in-depth understanding of the mechanism of drug
effects when an interaction at a specific target has not yet
been identified.
Going forward, it will be important that modeling with
regard to CV safety focuses increased attention on CV
effects such as contractility and structural damage, as
efforts have been relatively concentrated on CV parameters
that are readily measurable in a longitudinal manner from
short-term experiments. Much of the modeling space has
been dictated by the availability of data rather than the
merit of CV parameters to predict long-term safety risks.
The enormous interest and progress in QT has been driven
by a large number of molecules entering the clinic that
could be explained largely by a single mechanism. As
such, the hERG channel role in QT prolongation is now
much better understood and can readily be screened in
vitro. On the other hand, cardiovascular structural effects
(damage) downstream of ECG and hemodynamic changes
are relatively difficult to measure and predict, tend to be
chronic in nature, and arise from a greater number of
potential mechanisms. These therefore represent a poten-
tially large safety hazard. However, these effects could be
modeled at least empirically through application of techni-
ques for categorical variable modeling to preclinical cardio-
vascular data.
The relative rarity of cardiovascular damage in the clinic
normally means that a strong safety signal will only emerge
in large pivotal trials or investigations undertaken through
postmarketing surveillance. At this stage this is costly to
the sponsor. The challenge is therefore to quantify and pre-
dict risk of long-term CV safety issues from more frequently
observed CV parameter changes.
Systems modeling may be able to help predict these
chronic effects in the clinic as preclinical pathology read-
outs are further quantified and combined with short-term
parameter changes that have successfully been modeled to
date.
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